Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPLE
2024-517307-37-00Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, mercaptopurine and tioguanine in Nonhematologic neoplasms, solid tumor and hepatocellular carcinoma (HCC), sponsored by Rigshospitalet. Primary endpoints: Safety, tolerability, MTD and/or RP2D of atezolizumab in combination with 6-thioguanine and 6-mercaptopurine (Phase Ib) and Objective response rate (ORR) with atezolizumab, 6-thioguanine and 6-mercaptopurine (Phase II). Started Sep 2022; status: completed.
02
Drugs
atezolizumabmercaptopurinetioguanine
03
Conditions
Nonhematologic neoplasmssolid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-517307-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517307-37-00.